Puma Biotechnology (PBYI) Share-based Compensation (2012 - 2026)

Puma Biotechnology has reported Share-based Compensation for 15 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 6.42% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (down 13.68% YoY), and the FY2025 full-year result was $6.9 million, down 15.78% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.9 million, up from $1.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $3.2 million in Q2 2022, with the low at $1.6 million in Q4 2025.
• Historically, Share-based Compensation has averaged $2.3 million across 5 years, with a median of $2.4 million in 2024.
• The largest YoY upside for Share-based Compensation was 117.78% in 2022 against a maximum downside of 82.35% in 2022.
• Puma Biotechnology's Share-based Compensation stood at $2.6 million in 2022, then slipped by 7.46% to $2.4 million in 2023, then fell by 27.96% to $1.8 million in 2024, then decreased by 7.71% to $1.6 million in 2025, then rose by 17.25% to $1.9 million in 2026.
• The last three Share-based Compensation figures came in at $1.9 million (Q1 2026), $1.6 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.